Cellebrite DI Ltd. (CLBT)
NASDAQ: CLBT · Real-Time Price · USD
18.28
+0.08 (0.44%)
At close: Dec 5, 2025, 4:00 PM EST
18.21
-0.07 (-0.38%)
After-hours: Dec 5, 2025, 7:12 PM EST
Cellebrite DI Revenue
Cellebrite DI had revenue of $126.03M in the quarter ending September 30, 2025, with 17.94% growth. This brings the company's revenue in the last twelve months to $455.90M, up 18.37% year-over-year. In the year 2024, Cellebrite DI had annual revenue of $401.20M with 23.41% growth.
Revenue (ttm)
$455.90M
Revenue Growth
+18.37%
P/S Ratio
9.57
Revenue / Employee
$390,662
Employees
1,167
Market Cap
4.47B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apple | 416.16B |
| Microsoft | 293.81B |
| NVIDIA | 187.14B |
| Taiwan Semiconductor Manufacturing Company | 119.13B |
| International Business Machines | 65.40B |
| Broadcom | 59.93B |
| Oracle | 59.02B |
| Cisco Systems | 57.70B |
CLBT News
- 7 hours ago - Cellebrite: Solid Setup Going Into Next Year - Seeking Alpha
- 1 day ago - 10 AI Stocks Worth Buying Right Now - The Motley Fool
- 3 days ago - Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript - Seeking Alpha
- 3 days ago - Cellebrite Completes Acquisition of Corellium, Extending the Industry's Most Advanced AI-Powered Digital Investigation Platform - GlobeNewsWire
- 14 days ago - Cellebrite DI: Strong Q3, But Valuation And Technical Issues Could Weigh On The Stock (Rating Downgrade) - Seeking Alpha
- 16 days ago - Should Investors Buy Shares of Cellebrite Alongside Portolan Capital as They Double Down on the Stock? - The Motley Fool
- 18 days ago - Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter - The Motley Fool
- 22 days ago - Why Cellebrite Stock Is Skyrocketing Today - The Motley Fool